Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

Sakurai Y, Kolokoltsov AA, Chen CC, Tidwell MW, Bauta WE, Klugbauer N, Grimm C, Wahl-Schott C, Biel M, Davey RA.

Science. 2015 Feb 27;347(6225):995-8. doi: 10.1126/science.1258758.

2.

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ.

PLoS One. 2013;8(4):e60579. doi: 10.1371/journal.pone.0060579. Epub 2013 Apr 5.

3.

Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection.

Miller ME, Adhikary S, Kolokoltsov AA, Davey RA.

J Virol. 2012 Jul;86(14):7473-83. doi: 10.1128/JVI.00136-12. Epub 2012 May 9.

4.

GRB2 interaction with the ecotropic murine leukemia virus receptor, mCAT-1, controls virus entry and is stimulated by virus binding.

Chen Z, Kolokoltsov AA, Wang J, Adhikary S, Lorinczi M, Elferink LA, Davey RA.

J Virol. 2012 Feb;86(3):1421-32. doi: 10.1128/JVI.05993-11. Epub 2011 Nov 16.

5.

Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.

Kolokoltsov AA, Adhikary S, Garver J, Johnson L, Davey RA, Vela EM.

Arch Virol. 2012 Jan;157(1):121-7. doi: 10.1007/s00705-011-1115-8. Epub 2011 Sep 25.

PMID:
21947546
6.

Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver.

Desai MM, Gong B, Chan T, Davey RA, Soong L, Kolokoltsov AA, Sun J.

Gastroenterology. 2011 Aug;141(2):674-85, 685.e1-6. doi: 10.1053/j.gastro.2011.04.060. Epub 2011 May 6.

7.

The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus.

Hunt CL, Kolokoltsov AA, Davey RA, Maury W.

J Virol. 2011 Jan;85(1):334-47. doi: 10.1128/JVI.01278-09. Epub 2010 Nov 3.

8.

Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes.

Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA.

PLoS Pathog. 2010 Sep 16;6(9):e1001110. doi: 10.1371/journal.ppat.1001110.

9.

Critical role for the host GTPase-activating protein ARAP2 in InlB-mediated entry of Listeria monocytogenes.

Gavicherla B, Ritchey L, Gianfelice A, Kolokoltsov AA, Davey RA, Ireton K.

Infect Immun. 2010 Nov;78(11):4532-41. doi: 10.1128/IAI.00802-10. Epub 2010 Sep 7.

10.

CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells.

Chao C, Han X, Ives K, Park J, Kolokoltsov AA, Davey RA, Moyer MP, Hellmich MR.

Int J Cancer. 2010 Feb 15;126(4):864-75. doi: 10.1002/ijc.24845.

11.

Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening.

Kolokoltsov AA, Saeed MF, Freiberg AN, Holbrook MR, Davey RA.

Drug Dev Res. 2009 Jun 1;70(4):255-265.

12.

Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus.

Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA.

PLoS Pathog. 2008 Aug 29;4(8):e1000141. doi: 10.1371/journal.ppat.1000141.

13.

Alphavirus production is inhibited in neurofibromin 1-deficient cells through activated RAS signalling.

Kolokoltsova OA, Domina AM, Kolokoltsov AA, Davey RA, Weaver SC, Watowich SJ.

Virology. 2008 Jul 20;377(1):133-42. doi: 10.1016/j.virol.2008.03.025. Epub 2008 May 15.

14.
15.

Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus.

Kolokoltsov AA, Deniger D, Fleming EH, Roberts NJ Jr, Karpilow JM, Davey RA.

J Virol. 2007 Jul;81(14):7786-800. Epub 2007 May 9.

16.

Targeting and penetration of virus receptor bearing cells by nanoparticles coated with envelope proteins of Moloney murine leukemia virus.

Deniger DC, Kolokoltsov AA, Moore AC, Albrecht TB, Davey RA.

Nano Lett. 2006 Nov;6(11):2414-21.

PMID:
17090066
17.

Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.

Kolokoltsov AA, Wang E, Colpitts TM, Weaver SC, Davey RA.

Am J Trop Med Hyg. 2006 Oct;75(4):702-9.

PMID:
17038698
18.

Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins.

Fleming EH, Kolokoltsov AA, Davey RA, Nichols JE, Roberts NJ Jr.

J Virol. 2006 Dec;80(24):12160-70. Epub 2006 Sep 27.

19.

Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth.

Chao C, Goluszko E, Lee YT, Kolokoltsov AA, Davey RA, Uchida T, Townsend CM Jr, Hellmich MR.

Oncogene. 2007 Feb 15;26(7):1013-9. Epub 2006 Aug 14.

PMID:
16909104
20.

Determining functionally important amino acid residues of the E1 protein of Venezuelan equine encephalitis virus.

Negi SS, Kolokoltsov AA, Schein CH, Davey RA, Braun W.

J Mol Model. 2006 Sep;12(6):921-9. Epub 2006 Apr 11.

PMID:
16607494
21.

Novel, rapid assay for measuring entry of diverse enveloped viruses, including HIV and rabies.

Saeed MF, Kolokoltsov AA, Davey RA.

J Virol Methods. 2006 Aug;135(2):143-50. Epub 2006 Apr 3.

PMID:
16584792
23.
24.

SRC regulates constitutive internalization and rapid resensitization of a cholecystokinin 2 receptor splice variant.

Chao C, Ives KL, Goluszko E, Kolokoltsov AA, Davey RA, Townsend CM Jr, Hellmich MR.

J Biol Chem. 2005 Sep 30;280(39):33368-73. Epub 2005 Aug 3.

26.

Supplemental Content

Loading ...
Support Center